Figure 1
Figure 1. Activation of mTORC1 and mTORC2 signaling in clinical lymphoma samples. MCL samples (n = 10) were stained using antibodies to rictor, raptor, and autophosphorylated mTOR as well as phosphorylation site-specific antibodies for targets downstream of mTORC1 (phospho-Thr37/46-4EBP1, phospho-Ser235/236-ribosomal S6 protein) and mTORC2 (phospho-Ser473-Akt). Similar results were observed in all 10 specimens.

Activation of mTORC1 and mTORC2 signaling in clinical lymphoma samples. MCL samples (n = 10) were stained using antibodies to rictor, raptor, and autophosphorylated mTOR as well as phosphorylation site-specific antibodies for targets downstream of mTORC1 (phospho-Thr37/46-4EBP1, phospho-Ser235/236-ribosomal S6 protein) and mTORC2 (phospho-Ser473-Akt). Similar results were observed in all 10 specimens.

Close Modal

or Create an Account

Close Modal
Close Modal